Tempus AI (TEM), announces an expansion to its collaboration with Takeda (TAK)hat takes a data-first approach to research and development, with the aim of enhancing Takeda’s oncology research and development efforts. After an initial collaboration that leveraged Tempus’ de-identified multimodal datasets, this new agreement will expand upon that work. Takeda will combine Tempus’ multimodal real-world datasets and Tempus’ biological modeling capabilities to advance Takeda’s pipeline of cancer therapeutics, which includes antibody-drug conjugates ADCs , small molecules, bispecifics and gamma delta T-cell therapies. Takeda researchers will use Tempus’ analytics platform, Lens, to gain real-time access to de-identified patient records as well as a suite of AI-enabled tools to accelerate critical insights for Takeda’s drug development efforts. Initial work has resulted in research that will be presented at an upcoming medical congress.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Cathie Wood’s ARK Investment bought 61K shares of Tempus AI today
- Largest borrow rate increases among liquid names
- Cathie Wood’s ARK Investment bought 201K shares of Tempus AI today
- Tempus announces real world data collaboration with BioNTech
- tempus AI Inc Class A put volume heavy and directionally bearish